Hypertension, brain damage and cognitive decline

Current Hypertension Reports

Volumn 15, Issue 6, 2013, Pages 547-558

  Gąsecki, Dariusz ^a   Kwarciany, Mariusz ^a   Nyka, Walenty ^a   Narkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Ageing; Atherosclerosis; Brain; Cerebrovascular disease; Cognition; Cognitive decline; Dementia; Hypertension; Risk factors; Treatment

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIURETIC AGENT; EPROSARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN;

AGING; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN METABOLISM; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; GRAY MATTER; HEREDITY; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MENTAL STRESS; MILD COGNITIVE IMPAIRMENT; MIXED DEPRESSION AND DEMENTIA; MULTIINFARCT DEMENTIA; PREVALENCE; PULSE PRESSURE; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION; WHITE MATTER;

AGING; ANIMALS; BRAIN DAMAGE, CHRONIC; COGNITION; COGNITION DISORDERS; DEMENTIA; HUMANS; HYPERTENSION;

EID: 84890114937     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0398-4     Document Type: Article

References (140)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-74.
2. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119(4):421-33. doi: 10.1007/s00401-010-0654-5.
3. • Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571-87. doi: 10.1007/s00401-011-0826-y. Analysis of specific pathways involved in Alzheimer disease.
4. Barodka VM, Joshi BL, Berkowitz DE, Hogue CW, Nyhan D. Review article: implications of vascular aging. Anesth Analg. 2011;112(5):1048-60. doi: 10.1213/ANE.0b013e3182147e3c.
5. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17(2):63-7.
6. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010;6(2):98-103. doi: 10.1016/j.jalz.2010.01.010.
7. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-81. doi: 10.1001/archneur.63.5. 674.
8. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-92.
9. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-8.
10. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry. 1998;6(2 Suppl 1):S3-18.
11. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22(4):575-80.
12. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am. 2002;86(3):477-99.
13. •• Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013. doi: 10.1093/brain/awt188. Article summarizing the contribution of cerebrovascular disease to neurodegenerative diseases confirmed by autopsy.
14. Jellinger KA, Attems J. Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol. 2012;31(2):87-98.
15. Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol. 2006;60(6):677-87. doi: 10.1002/ana.21009.
16. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-7.
17. Shehab A, Abdulle A. Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension. BMC Cardiovasc Disord. 2011;11:3. doi: 10.1186/1471-2261-11-3.
18. Mahoney JR, Verghese J, Goldin Y, Lipton R, Holtzer R. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc. 2010;16(5):877-89. doi: 10.1017/s1355617710000767.
19. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens. 2011;24(3):299-303. doi: 10.1038/ajh.2010.236.
20. Szewieczek J, Dulawa J, Gminski J, Kurek A, Legierska K, Francuz T, et al. Better cognitive and physical performance is associated with higher blood pressure in centenarians. J Nutr Health Aging. 2011;15(8):618-22.
21. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846-51.
22. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353-64.
23. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-81. doi: 10.1212/01.wnl.0000149519.47454.f2.
24. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-99. doi: 10.1016/s1474-4422(05)70141-1.
25. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55.
26. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51(3):410-4.
27. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. 2013;61(1):67-73. doi: 10.1111/jgs.12067.
28. Reijmer YD, van den Berg E, Dekker JM, Nijpels G, Stehouwer CD, Kappelle LJ, et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc. 2012;60(8):1426-33. doi: 10.1111/j.1532-5415.2012.04081.x.
29. • Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension. 2010;55(6):1352-9. doi: 10.1161/hypertensionaha.109.147389. Important study indicating that reduction of SBP may be effective in prevention of late-life dementia.
30. • Ronnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord. 2011;31(6):460-6. doi: 10.1159/000330020. Seminal study showing in a long-term follow-up (up to 40 years) that vascular risk factors increase the risk of dementia, particularly vascular and mixed dementia, but not AD.
31. Laitala VS, Kaprio J, Koskenvuo M, Raiha I, Rinne JO, Silventoinen K. Association and causal relationship of midlife obesity and related metabolic disorders with old age cognition. Curr Alzheimer Res. 2011;8(6):699-706.
32. Banach M, Hering D, Narkiewicz K, Mysliwiec M, Rysz J, Malyszko J. Lipids, blood pressure, kidney-what was new in 2012? Int J Pharmacol. 2012;8(8):659-78.
33. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects - A meta-analysis of randomized controlled trials. Int J Cardiol. 2013. doi: 10.1016/j.ijcard.2013.03.068.
34. Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens. 2012;26(11):641-3. doi: 10.1038/jhh.2012.3.
35. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999;53(9):1948-52.
36. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. 2003;27(2):260-8. doi: 10.1038/sj.ijo.802225.
37. Hebert LE, Scherr PA, Bennett DA, Bienias JL, Wilson RS, Morris MC, et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology. 2004;62(11):2021-4.
38. Tervo S, Kivipelto M, Hanninen T, Vanhanen M, Hallikainen M, Mannermaa A, et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord. 2004;17(3):196-203. doi: 10.1159/000076356.
39. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. JAMA. 1999;281(5):438-45.
40. Bohannon AD, Fillenbaum GG, Pieper CF, Hanlon JT, Blazer DG. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc. 2002;50(3):424-9.
41. Yasar S, Ko JY, Nothelle S, Mielke MM, Carlson MC. Evaluation of the effect of systolic blood pressure and pulse pressure on cognitive function: the Women's Health and Aging Study II. PLoS One. 2011;6(12):e27976. doi: 10.1371/journal.pone.0027976.
42. Kimm H, Lee PH, Shin YJ, Park KS, Jo J, Lee Y, et al. Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch Gerontol Geriatr. 2011;52(3):e117-22. doi: 10.1016/j.archger.2010.09.004.
43. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011;58(1):22-8. doi: 10.1161/hypertensionaha.110.163055.
44. Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: the canadian study of health and aging. Arch Neurol. 2010;67(2):187-92. doi: 10.1001/archneurol.2009.312.
45. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-5.
46. Molander L, Gustafson Y, Lovheim H. Longitudinal associations between blood pressure and dementia in the very old. Dement Geriatr Cogn Disord. 2010;30(3):269-76. doi: 10.1159/000320252.
47. Staessen JA, Richart T, Birkenhager WH. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension. 2007;49(3):389-400. doi: 10.1161/01.HYP.0000258151.00728.d8.
48. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-51.
49. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci. 2003;72(10):1125-33.
50. Ueda K, Kawano H, Hasuo Y, Fujishima M. Prevalence and etiology of dementia in a Japanese community. Stroke. 1992;23(6):798-803.
51. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997;315(7115):1045-9.
52. Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, et al. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord. 1998;9(3):175-80.
53. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58(8):1175-81.
54. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60(2):223-8.
55. Yang YH, Roe CM, Morris JC. Relationship between late-life hypertension, blood pressure, and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2011;26(6):457-62. doi: 10.1177/1533317511421779.
56. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 2001;64(6):575-611.
57. Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease. Neurobiol Aging. 2009;30(9):1512-4. doi: 10.1016/j.neurobiolaging.2007.10.020.
58. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27(12):1908-18. doi: 10.1038/sj.jcbfm.9600491.
59. • Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension. 2010;56(5):859-64. doi: 10.1161/hypertensionaha.110.160002. This article provides an interesting explanation of the role of hypertension in impairments in mobility, cognition, and mood.
60. Hajjar I, Quach L, Yang F, Chaves PH, Newman AB, Mukamal K, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation. 2011;123(8):858-65. doi: 10.1161/circulationaha.110.978114.
61. Panerai RB. Assessment of cerebral pressure autoregulation in humans-a review of measurement methods. Physiol Meas. 1998;19(3):305-38.
62. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci. 2003;216(1):119-26.
63. • Appelman AP, Vincken KL, van der Graaf Y, Vlek AL, Witkamp TD, Mali WP, et al. White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. Cerebrovasc Dis. 2010;29(1):28-35. doi: 10.1159/000255971. Important study suggesting an independent role for WML in the pathogenesis of brain atrophy.
64. Romanowski CA, Wilkinson ID. Atrophy: when too much atrophy is too little brain. Neuroradiology. 2011;53 Suppl 1:S133-9. doi: 10.1007/s00234-011-0929-0.
65. Raz N, Rodrigue KM, Haacke EM. Brain aging and its modifiers: insights from in vivo neuromorphometry and susceptibility weighted imaging. Ann N Y Acad Sci. 2007;1097:84-93. doi: 10.1196/annals.1379.018.
66. Raz N, Rodrigue KM, Kennedy KM, Acker JD. Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology. 2007;21(2):149-57. doi: 10.1037/0894-4105.21.2.149.
67. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex. 2005;15(11):1676-89. doi: 10.1093/cercor/bhi044.
68. Chen X, Wen W, Anstey KJ, Sachdev PS. Effects of cerebrovascular risk factors on gray matter volume in adults aged 60-64 years: a voxel-based morphometric study. Psychiatry Res. 2006;147(2-3):105-14. doi: 10.1016/j.pscychresns.2006.01.009.
69. Taki Y, Goto R, Evans A, Zijdenbos A, Neelin P, Lerch J, et al. Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging. 2004;25(4):455-63. doi: 10.1016/j.neurobiolaging.2003. 09.002.
70. Strassburger TL, Lee HC, Daly EM, Szczepanik J, Krasuski JS, Mentis MJ, et al. Interactive effects of age and hypertension on volumes of brain structures. Stroke. 1997;28(7):1410-7.
71. Gunning-Dixon FM, Brickman AM, Cheng JC, Alexopoulos GS. Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry. 2009;24(2):109-17. doi: 10.1002/gps.2087.
72. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol. 1987;44(1):21-3.
73. • Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. doi: 10.1136/bmj.c3666. A systematic analysis of clinical relevance of WMH.
74. Xiong YY, Mok V. Age-related white matter changes. J Aging Res. 2011;2011:617927. doi: 10.4061/2011/617927.
75. •• Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. doi: 10.1016/S1474-4422(10)70104-6. Elegant review summarizing the evidence linking cerebral WMH to pathogenesis and clinical characteristics of cognitive decline.
76. Skoog I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord. 1998;9 Suppl 1:13-9.
77. Longstreth Jr WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27(8):1274-82.
78. • Verhaaren BF, Vernooij MW, de Boer R, Hofman A, Niessen WJ, van der Lugt A, et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension. 2013;61(6):1354-9. doi: 10.1161/hypertensionaha.111.00430. This study demonstrates that hypertension treatment could reduce WML progression in the general population.
79. Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata DK, Sharrett AR, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology. 2011;76(22):1879-85. doi: 10.1212/WNL.0b013e31821d753f.
80. Marcus J, Gardener H, Rundek T, Elkind MS, Sacco RL, Decarli C, et al. Baseline and longitudinal increases in diastolic blood pressure are associated with greater white matter hyperintensity volume: the northern Manhattan study. Stroke. 2011;42(9):2639-41. doi: 10.1161/strokeaha.111.617571.
81. Raz N, Yang YQ, Rodrigue KM, Kennedy KM, Lindenberger U, Ghisletta P. White matter deterioration in 15 months: latent growth curve models in healthy adults. Neurobiol Aging. 2012;33(2):429.e1-5. doi: 10.1016/j.neurobiolaging. 2010.11.018.
82. Salat DH, Williams VJ, Leritz EC, Schnyer DM, Rudolph JL, Lipsitz LA, et al. Inter-individual variation in blood pressure is associated with regional white matter integrity in generally healthy older adults. Neuroimage. 2012;59(1):181-92. doi: 10.1016/j.neuroimage.2011.07.033.
83. Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta. 2012;1822(3):361-9. doi: 10.1016/j.bbadis.2011.08.007.
84. Murray AD, Staff RT, McNeil CJ, Salarirad S, Starr JM, Deary IJ, et al. Brain lesions, hypertension and cognitive ageing in the 1921 and 1936 Aberdeen birth cohorts. Age (Dordr). 2012;34(2):451-9. doi: 10.1007/s11357-011-9233-5.
85. Maillard P, Carmichael O, Fletcher E, Reed B, Mungas D, DeCarli C. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology. 2012;79(5):442-8. doi: 10.1212/WNL.0b013e3182617136.
86. Haan M, Espeland MA, Klein BE, Casanova R, Gaussoin SA, Jackson RD, et al. Cognitive function and retinal and ischemic brain changes: the Women's Health Initiative. Neurology. 2012;78(13):942-9. doi: 10.1212/WNL. 0b013e31824d9655.
87. Loitfelder M, Seiler S, Schwingenschuh P, Schmidt R. Cerebral microbleeds: a review. Panminerva Med. 2012;54(3):149-60.
88. Waldstein SR, Rice SC, Thayer JF, Najjar SS, Scuteri A, Zonderman AB. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51(1):99-104. doi: 10.1161/hypertensionaha.107.093674.
89. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke. 2003;34(3):594-9. doi: 10.1161/01.str.0000060127. 96986.f4.
90. Lee AY, Jeong SH, Choi BH, Sohn EH, Chui H. Pulse pressure correlates with leukoaraiosis in Alzheimer disease. Arch Gerontol Geriatr. 2006;42(2):157-66. doi: 10.1016/j.archger.2005.06.009.
91. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009;118(1):87-102. doi: 10.1007/s00401-009-0498-z.
92. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009;40(4):1229-36. doi: 10.1161/strokeaha.108.532853.
93. Nation DA, Wierenga CE, Delano-Wood L, Jak AJ, Delis DC, Salmon DP, et al. Elevated pulse pressure is associated with age-related decline in language ability. J Int Neuropsychol Soc. 2010;16(5):933-8. doi: 10.1017/ s1355617710000548.
94. Pase MP, Pipingas A, Kras M, Nolidin K, Gibbs AL, Wesnes KA, et al. Healthy middle-aged individuals are vulnerable to cognitive deficits as a result of increased arterial stiffness. J Hypertens. 2010;28(8):1724-9. doi: 10.1097/HJH.0b013e32833b1ee7.
95. Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. J Alzheimers Dis. 2012;30(3):595-603. doi: 10.3233/jad-2012-111697.
96. • Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press. 2011;20(5):274-83. doi: 10.3109/08037051.2011.566246. This paper systematically analyzes the associations between vascular stiffness and cognitive function and shows that vascular stiffness is greater in VaD compared with AD.
97. Zhong W, Cruickshanks KJ, Schubert CR, Carlsson CM, Chappell RJ, Klein BE, et al. Pulse Wave Velocity and Cognitive Function in Older Adults. Alzheimer Dis Assoc Disord. 2013. doi: 10.1097/WAD.0b013e3182949f06.
98. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension. 2008;52(1):37-43. doi: 10.1161/HYPERTENSIONAHA.107.108985.
99. Gustafson DR, Melchior L, Eriksson E, Sundh V, Blennow K, Skoog I. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging. 2010;31(6):910-6. doi: 10.1016/j.neurobiolaging.2008.07.015.
100. Bourassa EA, Sved AF, Speth RC. Angiotensin modulation of rostral ventrolateral medulla (RVLM) in cardiovascular regulation. Mol Cell Endocrinol. 2009;302(2):167-75. doi: 10.1016/j.mce.2008.10.039.
101. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept. 2005;128(3):247-52. doi: 10.1016/j.regpep.2004.12. 027.
102. Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ. Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis. 2010;7(1-3):131-5. doi: 10.1159/000289222.
103. Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002;25(12):621-5.
104. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98(19):10966-71. doi: 10.1073/pnas.191044198.
105. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843-54. doi: 10.3233/JAD-2010- 091504.
106. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25(5):641-50. doi: 10.1016/j.neurobiolaging.2003.12.023.
107. Chuang YF, Hayden KM, Norton MC, Tschanz J, Breitner JC, Welsh-Bohmer KA, et al. Association between APOE epsilon4 allele and vascular dementia: the Cache County study. Dement Geriatr Cogn Disord. 2010;29(3):248-53. doi: 10.1159/000285166.
108. Yasuno F, Tanimukai S, Sasaki M, Ikejima C, Yamashita F, Kodama C, et al. Effect of plasma lipids, hypertension and APOE genotype on cognitive decline. Neurobiol Aging. 2012;33(11):2633-40. doi: 10.1016/j.neurobiolaging.2011.12.028.
109. Schuur M, van Swieten JC, Schol-Gelok S, Ikram MA, Vernooij MW, Liu F, et al. Genetic risk factors for cerebral small-vessel disease in hypertensive patients from a genetically isolated population. J Neurol Neurosurg Psychiatry. 2011;82(1):41-4. doi: 10.1136/jnnp.2009.176362.
110. Markovitz JH, Jonas BS, Davidson K. Psychologic factors as precursors to hypertension. Curr Hypertens Rep. 2001;3(1):25-32.
111. Sparrenberger F, Cichelero FT, Ascoli AM, Fonseca FP, Weiss G, Berwanger O, et al. Does psychosocial stress cause hypertension? A systematic review of observational studies. J Hum Hypertens. 2009;23(1):12-9. doi: 10.1038/jhh.2008.74.
112. • Jennings JR, Heim AF. From brain to behavior: hypertension's modulation of cognition and affect. Int J Hypertens. 2012;2012:701385. doi: 10.1155/2012/701385. This review provides evidence for an impact of blood pressure on the psychological factors.
113. Jennings JR, Zanstra Y. Is the brain the essential in hypertension? Neuroimage. 2009;47(3):914-21. doi: 10.1016/j.neuroimage.2009.04.072.
114. •• Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Statement summarizing the current knowledge regarding the contribution of vascular risk factors to cognitive impairment and dementia.
115. • Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43-53. doi: 10.1016/s1474-4422(10)70250-7. This article summarizes the effects of different approaches of RAA system inhibition on cognitive outcomes in ONTARGET/TRANSCEND trial.
116. • Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension. vol 2. United States2011. p. e6-7. An update of the meta-analysis of the placebo controlled trials regarding the blood-pressure lowering therapies for the primary prevention of dementia.
117. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008;26(8):1642-50. doi: 10.1097/HJH.0b013e328301a280.
118. Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich). 2012;14(2):78-84. doi: 10.1111/j.1751-7176.2011.00577.x.
119. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int. 2012;12(2):207-14. doi: 10.1111/j.1447-0594.2011.00746.x.
120. van Vliet P, Westendorp RG, van Heemst D, de Craen AJ, Oleksik AM. Cognitive decline precedes late-life longitudinal changes in vascular risk factors. J Neurol Neurosurg Psychiatry. 2010;81(9):1028-32. doi: 10.1136/jnnp.2009.182519.
121. Vicario A, del Sueldo MA, Zilberman JM, Cerezo GH. Cognitive evolution in hypertensive patients: a six-year follow-up. Vasc Health Risk Manag. 2011;7:281-5. doi: 10.2147/vhrm.s18777.
122. Vuorinen M, Solomon A, Rovio S, Nieminen L, Kareholt I, Tuomilehto J, et al. Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dement Geriatr Cogn Disord. 2011;31(2):119-25. doi: 10.1159/000323810.
123. Watfa G, Rossignol P, Kearney-Schwartz A, Fay R, Bracard S, Felblinger J, et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens. 2010;28(12):2485-93. doi: 10.1097/HJH.0b013e32833e4108.
124. • Jennings JR, Mendelson DN, Muldoon MF, Ryan CM, Gianaros PJ, Raz N, et al. Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure. J Hum Hypertens. 2012;26(5):295-305. doi: 10.1038/jhh.2011.31. This is a novel study demonstrating that essential hypertension is associated with grey matter shrinkage, and that reduction of BP may not counter that trend.
125. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
126. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-28. doi: 10.1016/s1474-4422(11)70072-2.
127. Jefferson AL, Tate DF, Poppas A, Brickman AM, Paul RH, Gunstad J, et al. Lower cardiac output is associated with greater white matter hyperintensities in older adults with cardiovascular disease. J Am Geriatr Soc. 2007;55(7):1044-8. doi: 10.1111/j.1532-5415.2007.01226.x.
128. Singh-Manoux A, Sabia S, Kivimaki M, Shipley MJ, Ferrie JE, Marmot MG. Cognition and incident coronary heart disease in late midlife: the Whitehall II study. Intelligence. 2009;37(6):529-34. doi: 10.1016/j.intell.2008.12.001.
129. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28(2):316-21.
130. Kähönen-Väre M, Brunni-Hakala S, Lindroos M, Pitkala K, Strandberg T, Tilvis R. Left ventricular hypertrophy and blood pressure as predictors of cognitive decline in old age. Aging Clin Exp Res. 2004;16(2):147-52.
131. Mitchell GF, van Buchem MA, Sigurdsson S, Gotal JD, Jonsdottir MK, Kjartansson Ó, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility- Reykjavik study. Brain. 2011;134(Pt 11):3398-407. doi: 10.1093/brain/awr253.
132. Kotze MJ, van Rensburg SJ. Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease. Metab Brain Dis. 2012;27(3):255-66. doi: 10.1007/s11011-012-9296-8.
133. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of
134. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009;66(3):336-42. doi: 10.1001/archneurol.2008.582.
135. Mielke MM, Zandi PP, Shao H, Waern M, Östling S, Guo X, et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology. 2010;75(21):1888-95. doi: 10.1212/WNL.0b013e3181feb2bf.
136. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-9. doi: 10.1016/S1474-4422(08) 70143-1.
137. Grassi D, Ferri L, Cheli P, Di Giosia P, Ferri C. Cognitive decline as a consequence of essential hypertension. Curr Pharm Des. 2011;17(28):3032-8.
138. Guan JW, Huang CQ, Li YH, Wan CM, You C, Wang ZR, et al. No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. J Alzheimers Dis. 2011;27(4):799-807. doi: 10.3233/jad-2011-111160.
139. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis. 2010;20(3):903-14. doi: 10.3233/jad-2010-091552.
140. Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, et al. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). J Neurol Sci. 2012;322(1-2):64-70.